Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MEI Pharma, Inc.
Nurix Therapeutics, Inc.
Massachusetts General Hospital
Pfizer
BeOne Medicines
University of Florida
Sichuan Huiyu Pharmaceutical Co., Ltd
Eli Lilly and Company
Allogene Therapeutics
Novartis
Ascentage Pharma Group Inc.
AstraZeneca
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
LTZ Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
AbbVie
AbbVie
Novartis
UNC Lineberger Comprehensive Cancer Center
AbbVie
University of Pennsylvania
University of California, San Francisco
City of Hope Medical Center
OncoNano Medicine, Inc.
Century Therapeutics, Inc.
Verismo Therapeutics
Carna Biosciences, Inc.
Sana Biotechnology
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
University of Arizona
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Ohio State University Comprehensive Cancer Center
Regeneron Pharmaceuticals
Mayo Clinic
City of Hope Medical Center
Bristol-Myers Squibb
Accutar Biotechnology Inc
Iksuda Therapeutics Ltd.
University of Nebraska
AstraZeneca